Clinical trials: Physical activity
- Drug or intervention Physical activity
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Solid Tumors
MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors
The main purpose of this study was to assess the safety and tolerability of MSB0011359C. Study consists of dose-escalation part and an expansion part in participants with metastatic or locally advanced solid tumors, for which no…
- Trial name
- NCT02699515
- Testing
- MSB0011359C
- Where
- 18 sites in Japan, South Korea and 1 more
- Volunteers
- 114 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Choroidal Neovascularization (CNV)
Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).
- Trial name
- NCT01840410
- Testing
- Ranibizumab
- Where
- 59 sites in Australia, Canada and 19 more
- Volunteers
- 183 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis
The purpose of this study is to determine the effect of GBR 830 on biomarkers in atopic dermatitis to enable further studies in this indication.
- Trial name
- NCT02683928
- Testing
- GBR 830
- Where
- 17 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Ichnos Sciences SA
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
The primary objective of this study was to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT04401800
- Testing
- Lenvatinib, Tislelizumab
- Where
- 9 sites in China
- Volunteers
- 64 people
- Sponsor
- BeiGene
Cardiac Arrhythmia
EnSite Precision Observational Study
This document is a clinical investigation plan (CIP) for the EnSite Precision Observational Study. This clinical study is intended to quantify and characterize the usage of the EnSite Precision™ Cardiac Mapping System (Software…
- Trial name
- NCT03260244
- Testing
- cardiac mapping and radiofrequency ablation procedure
- Where
- 7 sites in United States
- Volunteers
- 1,065 people
- Sponsor
- Abbott Medical Devices
Erectile Dysfunction
Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.
This study investigates the safety and efficacy of a new dosage form of Vardenafil, an orodispersible tablet (ODT), and compares it to the safety and efficacy of a placebo (inactive) tablet in the treatment of erectile…
- Trial name
- NCT00655629
- Testing
- Vardenafil ODT (STAXYN, BAY38-9456)
- Where
- 40 sites in United States, Australia and 2 more
- Volunteers
- 339 people
- Sponsor
- Bayer
Multiple Myeloma
Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
This is a phase I/II, single arm, open label, two-part study that will assess safety, tolerability and clinical activity of GSK2857916 given in combination with a programmed cell death-1 (PD-1) inhibitor pembrolizumab in subjects…
- Trial name
- DREAMM 4 (NCT03848845)
- Testing
- belantamab mafodotin, Pembrolizumab
- Where
- 12 sites in United States, Canada and 2 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
Belantamab mafodotin (GSK2857916) is a first in class, antibody dependent cellular cytotoxicity (ADCC) enhanced, humanized immunoglobulin G1 (IgG1) antibody-drug conjugate (ADC) which binds specifically to B cell maturation…
- Trial name
- NCT03828292
- Testing
- Belantamab mafodotin, Bortezomib, Dexamethasone
- Where
- 4 sites in Japan
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Alzheimer Disease
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
The goal of the proposed study, is to adapt a positive emotion intervention for Alzheimer's Disease (AD) caregivers into a self-guided online format that incorporates social connection components and adaptive system feedback…
- Trial name
- SAGE-LEAF (NCT05562583)
- Testing
- SAGE LEAF
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- BrightOutcome
Psoriasis
A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis
This is a multi-center phase 2b study in subjects with moderate to severe chronic plaque-type psoriasis. Approximately 300 subjects will be enrolled at approximately 60 investigator sites in North America and Europe.
- Trial name
- NCT03384745
- Testing
- M1095 (Sonelokimab), Secukinumab
- Where
- 60 sites in United States, Bulgaria and 5 more
- Volunteers
- 313 people
- Sponsor
- Bond Avillion 2 Development LP
Systemic Lupus Erythematosus
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
International trial to evaluate the biological activity and safety of cenerimod (ACT-334441) in systemic lupus erythematosus (SLE) patients.
- Trial name
- NCT02472795
- Testing
- Cenerimod
- Where
- 18 sites in United States, Belarus and 4 more
- Volunteers
- 105 people
- Sponsor
- Viatris Innovation GmbH
Type 2 Diabetes Mellitus
A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes
The purposes of this study is to evaluate the efficacy and safety of SYR-472 when administered at a dose of 100 mg once weekly as an add-on to insulin therapy compared with placebo in patients with type 2 diabetes mellitus and…
- Trial name
- NCT02324569
- Testing
- SYR-472
- Where
- 65 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Takeda
Chronic Hepatitis B
Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment
The primary objectives of this study are to evaluate the safety and tolerability of multiple oral doses of selgantolimod and to evaluate the antiviral activity of selgantolimod in adult participants with chronic hepatitis B (CHB)…
- Trial name
- NCT03615066
- Testing
- Selgantolimod, TAF
- Where
- 10 sites in Canada, South Korea and 1 more
- Volunteers
- 67 people
- Sponsor
- Gilead Sciences
Anesthesia
The Influence of Age on EEG Signals and Consciousness During Anesthesia
This is a prospective, multi-center, non-invasive, interventional, data collection study to improve the current BIS algorithm in the elderly adult population.
- Trial name
- TIARA (NCT04765046)
- Testing
- Bispectral (BIS™) Complete Monitoring System
- Where
- 2 sites in Israel, Netherlands
- Volunteers
- 90 people
- Sponsor
- Medtronic - MITG
HIV Infection
MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)
The purpose of this study is to investigate the efficacy, safety, and tolerability of an investigational treatment for patients with HIV.
- Trial name
- NCT00443703
- Testing
- MK0518 (raltegravir), Comparator: KALETRA™ (lopinavir (+) ritonavir )
- Volunteers
- 352 people
- Sponsor
- Merck Sharp & Dohme LLC
Adenosine Deaminase Severe Combined Immunodeficiency
Registry Study of Revcovi Treatment in Patients With ADA-SCID
This registry study is being conducted in patients with adenosine deaminase severe combined immune deficiency (ADA-SCID) who require enzyme replacement therapy (ERT) treatment with Revcovi.
- Trial name
- NCT03878069
- Testing
- elapegademase-lvlr
- Where
- 14 sites in United States
- Volunteers
- 32 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Dyslipidemia
Study of Lipid Control in Hyperlipidemic Participants (MK-0653-179)
This study is being done to see whether dietary and medicinal measures compliant with hyperlipidemia treatment guidelines will result in achieving target lipid values and to evaluate the total risk of cardiovascular disease in…
- Trial name
- NCT01436253
- Testing
- Lifestyle Changes, Hypolipemics
- Volunteers
- 2,196 people
- Sponsor
- Organon and Co
Spinal Stenosis, Lumbar Region, With Neurogenic Claudication
The MOTION Study - Treatment of LSS With the MILD Procedure
Prospective, multicenter, randomized controlled clinical study examining functional improvement in lumbar spinal stenosis (LSS) patients with neurogenic claudication who are treated with the MILD procedure plus conventional…
- Trial name
- NCT03610737
- Testing
- MILD Procedure, Conventional Medical Management (CMM)
- Where
- 18 sites in United States
- Volunteers
- 155 people
- Sponsor
- Vertos Medical, Inc.
Diabetes Mellitus, Non-Insulin-Dependent
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.
- Trial name
- NCT00411554
- Testing
- sitagliptin phosphate, Comparator: voglibose
- Volunteers
- 319 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.
The main objective of this trial is to investigate the effect of multiple oral dosing of high dose BI 1467335 over 28 days and multiple oral dosing of low dose BI 1467335 over 42 days on MAO-B occupancy in the brain compared to…
- Trial name
- NCT03927209
- Testing
- BI 1467335
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.